At this year’s American Heart Association (AHA) Scientific Sessions, the latest insights from clinical studies were shared to inform high-quality care by cardiologists worldwide. Dr Sheila Hegde and Dr Sara Saberi presented findings from the EXPLORER-HCM Study into the benefits of mavacamten, a first-in-class selective cardiac myosin inhibitor, on the underlying pathophysiology of obstructive hypertrophic cardiomyopathy (HCM). Insights from these poster presentations were outlined in this article.
Latest articles
All articles
10 Mins
18th
December
Reducing the CV Risks of Smoking
Smoking is a major risk factor for cardiovascular disease (CVD) and responsible for around 25% of all CVD-related deaths worldwide…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.
11 Mins
18th
October
Factor XI/XIa Inhibition: ESC Update
The emerging class of agents targeting factor XI/XIa offers the paradigm-shifting possibility of ‘haemostasis-sparing anticoagulation’…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.